ViroCarb
ViroCarb Inc. is pioneering a paradigm shift in antiviral drug development by targeting a cellular process, RNA processing, essential for the replication of multiple viruses. Their mission is to develop and commercialize a broad-spectrum antiviral platform to address current and future viral infections with a single mechanism, aiming to improve patient outcomes and prepare for potential pandemics.
Industries
Nr. of Employees
small (1-50)
ViroCarb
2 Bloor Street West, suite 700, Toronto, Ontario, M4W 3E2
Products
Preclinical small-molecule broad-spectrum antiviral candidate
A selected preclinical small-molecule candidate that inhibits viral replication by modulating host RNA processing; demonstrated in vitro potency against coronaviruses, adenoviruses, and influenza, with favorable selectivity index, high oral bioavailability, and no observed toxicity in repeat-dose mouse studies.
Preclinical small-molecule broad-spectrum antiviral candidate
A selected preclinical small-molecule candidate that inhibits viral replication by modulating host RNA processing; demonstrated in vitro potency against coronaviruses, adenoviruses, and influenza, with favorable selectivity index, high oral bioavailability, and no observed toxicity in repeat-dose mouse studies.
Services
Engagement with investors and industry partners to accelerate development and commercialization of antiviral candidates.
Collaborative research arrangements with academic teams for mechanism-of-action studies, target identification, and preclinical research.
Engagement with investors and industry partners to accelerate development and commercialization of antiviral candidates.
Collaborative research arrangements with academic teams for mechanism-of-action studies, target identification, and preclinical research.
Expertise Areas
- Broad-spectrum antiviral drug discovery
- Host-targeted therapeutics (RNA processing modulation)
- Preclinical pharmacology and toxicology
- In vitro antiviral assay development and analysis
Key Technologies
- Small-molecule therapeutics
- Host-directed antiviral mechanism (RNA processing modulation)
- Cell-based antiviral assays
- Resistance profiling
News & Updates
ViroCarb Inc. Transformational broad-spectrum antiviral therapy
ViroCarb Inc. is developing a groundbreaking proprietary class of antiviral drug candidates, focusing on a host-directed approach that impedes the replication of multiple viruses without producing drug resistance.
ViroCarb Inc. Marking a paradigm shift in antiviral drug development
ViroCarb is taking a pioneering approach to address the urgent need for effective treatments of viral infections by impairing RNA processing, a crucial cellular process for viral replication.
ViroCarb Inc. Transformational broad-spectrum antiviral therapy
ViroCarb Inc. is developing a groundbreaking proprietary class of antiviral drug candidates, focusing on a host-directed approach that impedes the replication of multiple viruses without producing drug resistance.
ViroCarb Inc. Marking a paradigm shift in antiviral drug development
ViroCarb is taking a pioneering approach to address the urgent need for effective treatments of viral infections by impairing RNA processing, a crucial cellular process for viral replication.